Catalyst Pharmaceuticals (FRA:CN2) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CN2 Catalyst Pharmaceuticals Inc FRA:CN2
93 GF Score
Price €27.30
GF Value €20.73
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Catalyst Pharmaceuticals Valuation Rank Related Terms

FRA:CN2
93GF Score
Catalyst Pharmaceuticals Inc FRA:CN2
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of €27.30 is trading 31.7% above its estimated GF Value™ of €20.73. GuruFocus considers Catalyst Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:CN2:

  • Valuation Rank:
  • GF Value™: €20.73 vs. price of €27.30 (31.7% above fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catalyst Pharmaceuticals Business Description

Other Exchanges CPRX:USACN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score

Get the complete analysis for FRA:CN2

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.30
Price
€20.73
GF Value